A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open, one-arm, two-centre, Phase II clinical safety pilot-study. The
trial is designed to gain initial safety and efficacy-related data on once-daily orally
administered ZD4054 10 mg in prior chemotherapy treated patients with metastatic
hormone-resistant prostate cancer.